Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Abstract The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency. Currently, the research on novel coronavirus is still in the primary stage. Based on the current published evidence, we systematically summarizes the epidemiology, clinical characteristics, diagnosis, treatment and prevention of knowledge surrounding COVID-19. This review in the hope of helping the public effectively recognize and deal with the 2019 novel coronavirus (SARS-CoV-2), and providing a reference for future studies.

[1]  S. Kaveri,et al.  Intravenous immunoglobulin as clinical immune-modulating therapy , 2015, Canadian Medical Association Journal.

[2]  Ik Joon Jo,et al.  MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study , 2016, The Lancet.

[3]  J. Tang,et al.  SARS: clinical presentation, transmission, pathogenesis and treatment options. , 2006, Clinical science.

[4]  Xiaogen Zhou,et al.  Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1 , 2020, bioRxiv.

[5]  Wei Li,et al.  [The curative effect observation of shuanghuanglian and penicillin on acute tonsillitis]. , 2002, Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology.

[6]  H. Hemilä.  Vitamin C intake and susceptibility to pneumonia. , 1997, The Pediatric infectious disease journal.

[7]  Herman Tse,et al.  Interspecies transmission and emergence of novel viruses: lessons from bats and birds , 2013, Trends in Microbiology.

[8]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[9]  A. Payer,et al.  University of Texas Medical Branch at Galveston. , 2000, Academic medicine : journal of the Association of American Medical Colleges.

[10]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[11]  Heshui Shi,et al.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.

[12]  J. Kellum,et al.  Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. , 2016, JAMA.

[13]  Richard J Simpson,et al.  Exercise and the Regulation of Immune Functions. , 2015, Progress in molecular biology and translational science.

[14]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[16]  Xingguang Li,et al.  Response to comments on "Cross‐species Transmission of the Newly Identified Coronavirus 2019‐nCoV” and “Codon bias analysis may be insufficient for identifying host(s) of a novel virus” , 2020 .

[17]  Khamitov Ra,et al.  Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures , 2008 .

[18]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[19]  Christian Drosten,et al.  The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells , 2020, bioRxiv.

[20]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[21]  P. Liang,et al.  Anti-SARS coronavirus agents: a patent review (2008 – present) , 2013, Expert opinion on therapeutic patents.

[22]  H T Lu,et al.  [Effect of combined treatment of Shuanghuanglian and recombinant interferon alpha 2a on coxsackievirus B3 replication in vitro]. , 2000, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[23]  C. Lam,et al.  The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. , 2005, Journal of alternative and complementary medicine.

[24]  RNA sequencing by direct tagmentation of RNA/DNA hybrids , 2020, Proceedings of the National Academy of Sciences.

[25]  Xin Chen,et al.  Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. , 2002, Life sciences.

[26]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of Medical Virology.

[27]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[28]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[29]  J. Tong,et al.  Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.

[30]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[31]  H. Balkhy,et al.  Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review , 2017, Journal of Infection and Public Health.

[32]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[33]  Hong Shan,et al.  Evidence for Gastrointestinal Infection of SARS-CoV-2 , 2020, Gastroenterology.

[34]  L. Mao,et al.  Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study , 2020, medRxiv.

[35]  Anil T Ahuja,et al.  Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. , 2003, Radiology.

[36]  Weier Wang,et al.  Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China , 2020, Journal of medical virology.

[37]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[38]  Q. Tao,et al.  Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases , 2020, Radiology.

[39]  V. A. Maksimov,et al.  [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. , 2008, Voprosy virusologii.

[40]  Taojiao Wang,et al.  Caution on Kidney Dysfunctions of COVID-19 Patients , 2020, medRxiv.

[41]  Taojiao Wang,et al.  Caution on Kidney Dysfunctions of 2019-nCoV Patients , 2020 .

[42]  Nicola Robinson,et al.  Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs , 2020, Chinese Journal of Integrative Medicine.

[43]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[44]  Manish Kaushik,et al.  Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: A prospective cohort study , 2015, Nephrology.

[45]  Alfonso J. Rodriguez-Morales,et al.  Coronavirus Disease 2019–COVID-19 , 2020, Clinical Microbiology Reviews.

[46]  J. Rocklöv,et al.  The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.

[47]  P. Niu,et al.  Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China , 2020, Cell Host & Microbe.

[48]  G. Leung,et al.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.

[49]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of medical virology.

[50]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[51]  Suxin Wan,et al.  Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.

[52]  K. High,et al.  Nutritional strategies to boost immunity and prevent infection in elderly individuals. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  Yunhui Liu,et al.  Potential interventions for novel coronavirus in China: A systematic review , 2020, Journal of medical virology.

[54]  M. Barreto,et al.  Infectious diseases epidemiology , 2006, Journal of Epidemiology and Community Health.

[55]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[56]  W. Liang,et al.  Clinical characteristics of 2019 novel coronavirus infection in China , 2020, medRxiv.

[57]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.

[58]  Maimuna S. Majumder,et al.  Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data , 2014, PLoS currents.

[59]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[60]  Zi-feng Yang,et al.  The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function , 2017, BMC Complementary and Alternative Medicine.

[61]  J. Cui,et al.  ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism , 2020, medRxiv.

[62]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[63]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  J. Robins,et al.  Transmission Dynamics and Control of Severe Acute Respiratory Syndrome , 2003, Science.

[65]  S. Polyak,et al.  Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. , 2008, Current medicinal chemistry.

[66]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[67]  Eric W. Bell,et al.  Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1 , 2020, bioRxiv.

[68]  R. Gandhi.  Clinical Characteristics of 2019 Novel Coronavirus Infection , 2020 .

[69]  J. Remais.  Modelling Environmentally-Mediated Infectious Diseases of Humans: Transmission Dynamics of Schistosomiasis in China , 2010, Advances in experimental medicine and biology.

[70]  Wei Liu,et al.  Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China , 2020, medRxiv.

[71]  R. Brookmeyer,et al.  Incubation periods of acute respiratory viral infections: a systematic review , 2009, The Lancet Infectious Diseases.

[72]  Kenneth D Mandl,et al.  Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China. , 2020, SSRN.

[73]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[74]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[75]  J. Lippolis,et al.  Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. , 2014, Journal of dairy science.

[76]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[77]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.